T cell decision-making decodes the dynamic antigenic landscape - Report - MDSpire

T cell decision-making decodes the dynamic antigenic landscape

  • By

  • Inbal Eizenberg-Magar

  • Lior Dayan

  • Benny Chain

  • Yaron E. Antebi

  • June 1, 2026

  • 0 min

Share

Clinical Report: T Cell Decision Processes Interpret the Evolving Antigenic Environment

Overview

Revise to specify implications of antigen concentration changes for immune responses and therapeutic strategies.

Background

The adaptive immune system must continuously interpret a diverse array of antigens, which can vary significantly in concentration and timing. Understanding how T cells respond to these dynamic antigenic environments is crucial for developing effective immunotherapies and vaccines. This review addresses the often-overlooked temporal aspects of antigen exposure and their role in shaping T cell responses.

Data Highlights

No numerical data presented in the article.

Key Findings

  • T cells are sensitive not only to antigen quantity but also to the rate of change in antigen concentration.
  • Dynamic antigen presentation affects T cell activation, differentiation, and memory formation.
  • Different T cell subsets (naïve, effector, memory) exhibit distinct activation thresholds and signaling kinetics.
  • Physiological context, including co-stimulatory signals and cytokines, influences T cell responses to antigens.
  • Manipulating antigen dynamics can enhance vaccine efficacy and inform therapeutic strategies.

Clinical Implications

Clinicians should consider the dynamic nature of antigen exposure when designing vaccines and immunotherapies. Understanding T cell decision-making processes can lead to improved strategies for modulating immune responses in various clinical settings.

Conclusion

Incorporating the dynamics of antigen exposure into immunological models may enhance our understanding of T cell behavior and improve therapeutic interventions. This perspective is essential for advancing clinical practices in immunotherapy and vaccine development.

Related Resources & Content

  1. Frontiers in Immunology, 2026 -- Limited adaptability of virtual memory CD8 T cells to chronic viral infection
  2. The Journal of Infectious Diseases, 2023 -- Effect of Viral Antigen Mismatch on Antiviral T-Cell Response and Immunotherapeutic Efficacy Against Adult T-Cell Leukemia/Lymphoma
  3. Bone Marrow Transplantation, 2022 -- Exploring the Role of TCR Sequencing in Graft-Versus-Host Disease Management
  4. The ASCO Post, 2015 -- Adding CD47 to Artificial Antigen-Presenting Cells May Stimulate T-Cell Responses and Improve Functionality
  5. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy | New England Journal of Medicine
  6. CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial | Nature Medicine
  7. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update - PubMed
  8. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy | New England Journal of Medicine
  9. CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial | Nature Medicine
  10. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update - PubMed

Original Source(s)

Related Content